Keyphrases
Pancreatic Ductal Adenocarcinoma
100%
Mucin 1 (MUC1)
100%
Stimuli-responsive
100%
Combinatorial Chemotherapy
100%
Gemcitabine Plus Cisplatin
100%
Nanoparticles
66%
Sequential Therapy
40%
Effective Treatment
40%
Tumor-associated MUC1
40%
PDAC Cells
40%
Therapeutic Efficacy
40%
Gemcitabine
40%
Cancer Causes
26%
Cancer Mortality
26%
Invasiveness
20%
Cisplatin
20%
Targeted Therapeutics
20%
Ductal Adenocarcinoma
20%
Resistant Behavior
20%
Nanoplatform
20%
5-year Survival
20%
Desmoplastic
20%
Early Metastasis
20%
Syngeneic
20%
Patient-derived Xenograft
20%
Resistance to Therapy
20%
Mechanistic Role
20%
Worse Prognosis
20%
Therapeutic Efficiency
20%
TAB004
20%
Sequential Delivery System
20%
Nanocarriers
20%
Biological Stability
20%
Therapeutic Effectiveness
20%
Xenograft Mice
20%
Tumor Metastasis
20%
Tumor Stroma
20%
Malignant Disease
13%
Mouse Model
13%
United States
13%
High Mortality
13%
Biodistribution
13%
Controlled Delivery
13%
Transgenic
13%
Bench-to-bedside Translation
13%
DNA Damage
13%
Clinical Outcomes
13%
Tumor
13%
Pharmacokinetics
13%
Pharmacology, Toxicology and Pharmaceutical Science
Gemcitabine
100%
Pancreas Adenocarcinoma
100%
Cisplatin
85%
Nanoparticle
66%
Chemotherapy
66%
Neoplasm
38%
Mucin 1
28%
Malignant Neoplasm
19%
Disease
19%
Combination Therapy
19%
Nanocarrier
14%
Adenocarcinoma
14%
Survival Rate
14%
Pharmacokinetics
9%
Metastasis
9%
Biodistribution
9%
Mouse Model
9%
Mouse
9%